Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Jun;59(6):628-636.
doi: 10.1111/jcpp.12830. Epub 2017 Oct 24.

Omega-3 Supplementation Associated With Improved Parent-Rated Executive Function in Youth With Mood Disorders: Secondary Analyses of the Omega 3 and Therapy (OATS) Trials

Affiliations
Free PMC article
Randomized Controlled Trial

Omega-3 Supplementation Associated With Improved Parent-Rated Executive Function in Youth With Mood Disorders: Secondary Analyses of the Omega 3 and Therapy (OATS) Trials

Anthony T Vesco et al. J Child Psychol Psychiatry. .
Free PMC article

Abstract

Background: Improvements in executive functioning (EF) may lead to improved quality of life and lessened functional impairment for children with mood disorders. The aim was to assess the impact of omega-3 supplementation (Ω3) and psychoeducational psychotherapy (PEP), each alone and in combination, on EF in youth with mood disorders. We completed secondary analyses of two randomized controlled trials (RCTs) of Ω3 and PEP for children with depression and bipolar disorder.

Methods: Ninety-five youths with depression or bipolar disorder not otherwise specified/cyclothymic disorder were randomized in 12-week RCTs. Two capsules (Ω3 or placebo) were given twice daily (1.87 g Ω3 total daily, mostly eicosapentaenoic acid). Families randomized to PEP participated in twice-weekly 50-min sessions. Analyses assess impact of interventions on the Behavior Rating Inventory of Executive Functioning (BRIEF) parent-report Global Executive Composite (GEC) and two subscales, Behavior Regulation (BRI) and Metacognition (MI) Indices. Intent-to-treat repeated measures ANOVAs, using multiple imputation for missing data, included all 95 randomized participants. Trials were registered with www.clinicaltrials.gov, NCT01341925 & NCT01507753.

Results: Participants receiving Ω3 (aggregating combined and monotherapy) improved significantly more than aggregated placebo on GEC (p = .001, d = .70), BRI (p = .004, d = .49), and MI (p = .04, d = .41). Ω3 alone (d = .49) and combined with PEP (d = .67) each surpassed placebo on GEC. Moderation by attention-deficit/hyperactivity disorder (ADHD) comorbidity was nonsignificant although those with ADHD showed nominally greater gains. PEP monotherapy had negligible effect.

Conclusions: Decreased impairment in EF was associated with Ω3 supplementation in youth with mood disorders. Research examining causal associations of Ω3, EF, and mood symptoms is warranted.

Keywords: School children; bipolar disorder; depression; nutrition; psychotherapy.

Conflict of interest statement

Conflict of interest statement: See Acknowledgements for disclosures.

Figures

Figure 1
Figure 1
CONSORT diagram illustrating participant recruitment, randomization allocation, and completion/attrition. BRIEF was collected at screening (pre-intervention) and after 12 weeks of intervention.

Comment in

Similar articles

See all similar articles

Cited by 1 article

Publication types

Associated data

Feedback